KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Amortization of Deferred Charges (2019 - 2021)

Resmed (RMD) has disclosed Amortization of Deferred Charges for 4 consecutive years, with $8.5 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Amortization of Deferred Charges fell 18.28% year-over-year to $8.5 million, compared with a TTM value of $32.9 million through Sep 2021, up 6.05%, and an annual FY2021 reading of $34.8 million, up 31.06% over the prior year.
  • Amortization of Deferred Charges was $8.5 million for Q3 2021 at Resmed, down from $9.0 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $10.4 million in Q3 2020 and bottomed at $6.0 million in Q3 2019.
  • Average Amortization of Deferred Charges over 3 years is $7.8 million, with a median of $7.5 million recorded in 2020.
  • The sharpest move saw Amortization of Deferred Charges soared 74.78% in 2020, then dropped 18.28% in 2021.
  • Year by year, Amortization of Deferred Charges stood at $6.4 million in 2019, then grew by 17.75% to $7.5 million in 2020, then rose by 13.73% to $8.5 million in 2021.
  • Business Quant data shows Amortization of Deferred Charges for RMD at $8.5 million in Q3 2021, $9.0 million in Q2 2021, and $7.9 million in Q1 2021.